Most Read Articles
Christina Lau, 02 Jan 2020

Tolvaptan improves dyspnoea, increases sodium levels and reduces body weight in patients with acute heart failure (HF) with or without hyponatraemia, but no significant effect is seen in mortality or rehospitalization, according to a recent meta-analysis.

Pearl Toh, 15 Apr 2020
Transcatheter aortic valve replacement (TAVR) in patients with bicuspid aortic stenosis who are at low surgical risk appears to be safe with low rates of death or disabling stroke at 30 days, according to a study presented at the ACC.20/WCC Virtual Meeting.

PCSK9 Inhibitor well tolerated in patients with statin intolerance

17 May 2020

Patients with self-reported statin intolerance may benefit from proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, which have been shown to lower atherogenic lipid markers in this population, suggests a recent study.

The authors conducted a retrospective chart review to describe the tolerability of evolocumab and alirocumab and to examine their efficacy and obtainability. They included adult patients with self-reported statin intolerance who were prescribed a PCSK9 inhibitor. Patient-reported side effects, laboratory values and insurance information were also obtained and assessed.

PCSK9 inhibitor was prescribed to 55 patients during the study period. Forty-two patients initiated therapy, and 34 had at least one follow-up visit. Although adverse events occurred in those prescribed PCSK9 inhibitors, including myalgia (n=5; 14.7 percent), flu-like symptoms (n=4; 11.8 percent) and fatigue (n=1; 2.9 percent), only two patients (5.9 percent) discontinued treatment.

Low-density lipoprotein cholesterol (LDL-C) decreased by 48.7 percent (95 percent confidence interval [CI], –1.7 percent to 99.1 percent). Twenty patients (58.8 percent) were able to achieve a reduction of ≥50 percent in LDL-C.

In terms of obtainability, 44 (77.2 percent) of the 57 prescriptions written required prior authorization. Three (5.3 percent) were denied by insurance.

PCSK9 heightens LDL-C concentrations by interfering with normal physiologic hepatic LDL receptor (LDLR) recycling. By inhibiting PCSK9, LDLR recycling is improved, LDLR availability on hepatocyte cell surfaces is increased and blood LDL-C levels is reduced. This makes PCSK9 inhibition an effective therapeutic strategy for managing hypercholesterolaemia. [Vasc Health Risk Manag 2016;12:185-197]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Christina Lau, 02 Jan 2020

Tolvaptan improves dyspnoea, increases sodium levels and reduces body weight in patients with acute heart failure (HF) with or without hyponatraemia, but no significant effect is seen in mortality or rehospitalization, according to a recent meta-analysis.

Pearl Toh, 15 Apr 2020
Transcatheter aortic valve replacement (TAVR) in patients with bicuspid aortic stenosis who are at low surgical risk appears to be safe with low rates of death or disabling stroke at 30 days, according to a study presented at the ACC.20/WCC Virtual Meeting.